9705405-0

**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/43 — A1

(11) International Publication Number: **WO 96/34605**

(43) International Publication Date: 7 November 1996 (07.11.96)

(21) International Application Number: PCT/EP96/01881

(22) International Filing Date: 2 May 1996 (02.05.96)

(30) Priority Data:

| | | |
|---|---|---|
| 9508989.2 | 3 May 1995 (03.05.95) | GB |
| 9523655.0 | 18 November 1995 (18.11.95) | GB |

(71) Applicants *(for all designated States except US)*: SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19103 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BAX, Richard, Peregrine [GB/GB]; SmithKline Beecham Pharmaceuticals, Third Avenue, Harlow, Essex CM19 5AW (GB). RAMSEY, Mike, Gale [US/US]; SmithKline Beecham Pharmaceuticals, Bristol Industrial Park, Weaver Pike, Bristol, TN 37620 (US).

(74) Agent: THOMPSON, Clive, Beresford; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
*With international search report.*

(54) Title: COMPOSITION COMPRISING AMOXYCILLIN AND CLAVULANIC ACID

(57) Abstract

Paediatric aqueous liquid suspension formulations comprising amoxycillin trihydrate and potassium clavulanate in a ratio of from 6:1 to 8:1 are provided for use in a BID dosage regimen for treating bacterial infection.